Literature DB >> 21445056

Gain of function of mutant p53 by coaggregation with multiple tumor suppressors.

Jie Xu1, Joke Reumers, José R Couceiro, Frederik De Smet, Rodrigo Gallardo, Stanislav Rudyak, Ann Cornelis, Jef Rozenski, Aleksandra Zwolinska, Jean-Christophe Marine, Diether Lambrechts, Young-Ah Suh, Frederic Rousseau, Joost Schymkowitz.   

Abstract

Many p53 missense mutations possess dominant-negative activity and oncogenic gain of function. We report that for structurally destabilized p53 mutants, these effects result from mutant-induced coaggregation of wild-type p53 and its paralogs p63 and p73, thereby also inducing a heat-shock response. Aggregation of mutant p53 resulted from self-assembly of a conserved aggregation-nucleating sequence within the hydrophobic core of the DNA-binding domain, which becomes exposed after mutation. Suppressing the aggregation propensity of this sequence by mutagenesis abrogated gain of function and restored activity of wild-type p53 and its paralogs. In the p53 germline mutation database, tumors carrying aggregation-prone p53 mutations have a significantly lower frequency of wild-type allele loss as compared to tumors harboring nonaggregating mutations, suggesting a difference in clonal selection of aggregating mutants. Overall, our study reveals a novel disease mechanism for mutant p53 gain of function and suggests that, at least in some respects, cancer could be considered an aggregation-associated disease.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21445056     DOI: 10.1038/nchembio.546

Source DB:  PubMed          Journal:  Nat Chem Biol        ISSN: 1552-4450            Impact factor:   15.040


  48 in total

1.  Structural evolution of p53, p63, and p73: implication for heterotetramer formation.

Authors:  Andreas C Joerger; Sridharan Rajagopalan; Eviatar Natan; Dmitry B Veprintsev; Carol V Robinson; Alan R Fersht
Journal:  Proc Natl Acad Sci U S A       Date:  2009-10-07       Impact factor: 11.205

2.  Cytoplasmically sequestered wild-type p53 protein in neuroblastoma is relocated to the nucleus by a C-terminal peptide.

Authors:  A G Ostermeyer; E Runko; B Winkfield; B Ahn; U M Moll
Journal:  Proc Natl Acad Sci U S A       Date:  1996-12-24       Impact factor: 11.205

3.  A subset of tumor-derived mutant forms of p53 down-regulate p63 and p73 through a direct interaction with the p53 core domain.

Authors:  C Gaiddon; M Lokshin; J Ahn; T Zhang; C Prives
Journal:  Mol Cell Biol       Date:  2001-03       Impact factor: 4.272

4.  p53 family members in myogenic differentiation and rhabdomyosarcoma development.

Authors:  Hakan Cam; Heidi Griesmann; Michaela Beitzinger; Lars Hofmann; Rasa Beinoraviciute-Kellner; Markus Sauer; Nicole Hüttinger-Kirchhof; Claudia Oswald; Peter Friedl; Stefan Gattenlöhner; Christof Burek; Andreas Rosenwald; Thorsten Stiewe
Journal:  Cancer Cell       Date:  2006-10       Impact factor: 31.743

5.  Prognostic significance of p53 mutations in colon cancer at the population level.

Authors:  Wade S Samowitz; Karen Curtin; Khe-ni Ma; Sandra Edwards; Donna Schaffer; Mark F Leppert; Martha L Slattery
Journal:  Int J Cancer       Date:  2002-06-01       Impact factor: 7.396

6.  Quantitative analysis of residual folding and DNA binding in mutant p53 core domain: definition of mutant states for rescue in cancer therapy.

Authors:  A N Bullock; J Henckel; A R Fersht
Journal:  Oncogene       Date:  2000-03-02       Impact factor: 9.867

7.  A database of germline p53 mutations in cancer-prone families.

Authors:  Z Sedlacek; R Kodet; A Poustka; P Goetz
Journal:  Nucleic Acids Res       Date:  1998-01-01       Impact factor: 16.971

8.  Change of conformation of the DNA-binding domain of p53 is the only key element for binding of and interference with p73.

Authors:  Karim Bensaad; Morgane Le Bras; Keziban Unsal; Sabrina Strano; Giovanni Blandino; Osamu Tominaga; Dany Rouillard; Thierry Soussi
Journal:  J Biol Chem       Date:  2003-01-07       Impact factor: 5.157

9.  Some facts and thoughts: p73 as a tumor suppressor gene in the network of tumor suppressors.

Authors:  Lakshmanane Boominathan
Journal:  Mol Cancer       Date:  2007-04-03       Impact factor: 27.401

10.  Aggresomes: a cellular response to misfolded proteins.

Authors:  J A Johnston; C L Ward; R R Kopito
Journal:  J Cell Biol       Date:  1998-12-28       Impact factor: 10.539

View more
  196 in total

1.  Chaperoning of mutant p53 protein by wild-type p53 protein causes hypoxic tumor regression.

Authors:  Rajan Gogna; Esha Madan; Periannan Kuppusamy; Uttam Pati
Journal:  J Biol Chem       Date:  2011-12-06       Impact factor: 5.157

2.  Crystal Structures of IAPP Amyloidogenic Segments Reveal a Novel Packing Motif of Out-of-Register Beta Sheets.

Authors:  Angela B Soriaga; Smriti Sangwan; Ramsay Macdonald; Michael R Sawaya; David Eisenberg
Journal:  J Phys Chem B       Date:  2016-01-11       Impact factor: 2.991

3.  p53 reactivation with induction of massive apoptosis-1 (PRIMA-1) inhibits amyloid aggregation of mutant p53 in cancer cells.

Authors:  Luciana P Rangel; Giulia D S Ferretti; Caroline L Costa; Sarah M M V Andrade; Renato S Carvalho; Danielly C F Costa; Jerson L Silva
Journal:  J Biol Chem       Date:  2019-01-02       Impact factor: 5.157

4.  Protein mimetic amyloid inhibitor potently abrogates cancer-associated mutant p53 aggregation and restores tumor suppressor function.

Authors:  L Palanikumar; Laura Karpauskaite; Mohamed Al-Sayegh; Ibrahim Chehade; Maheen Alam; Sarah Hassan; Debabrata Maity; Liaqat Ali; Mona Kalmouni; Yamanappa Hunashal; Jemil Ahmed; Tatiana Houhou; Shake Karapetyan; Zackary Falls; Ram Samudrala; Renu Pasricha; Gennaro Esposito; Ahmed J Afzal; Andrew D Hamilton; Sunil Kumar; Mazin Magzoub
Journal:  Nat Commun       Date:  2021-06-25       Impact factor: 14.919

5.  Mutant p53 perturbs DNA replication checkpoint control through TopBP1 and Treslin.

Authors:  Kang Liu; Fang-Tsyr Lin; Joshua D Graves; Yu-Ju Lee; Weei-Chin Lin
Journal:  Proc Natl Acad Sci U S A       Date:  2017-04-24       Impact factor: 11.205

6.  Wild-type and mutant p53 mediate cisplatin resistance through interaction and inhibition of active caspase-9.

Authors:  Jacqueline L Y Chee; Suzan Saidin; David P Lane; Sai Mun Leong; Jacqueline E Noll; Paul M Neilsen; Yi Ting Phua; Hani Gabra; Tit Meng Lim
Journal:  Cell Cycle       Date:  2012-01-15       Impact factor: 4.534

7.  Dipeptide analysis of p53 mutations and evolution of p53 family proteins.

Authors:  Qiang Huang; Long Yu; Arnold J Levine; Ruth Nussinov; Buyong Ma
Journal:  Biochim Biophys Acta       Date:  2013-04-10

8.  Detection of the HIV-1 minus-strand-encoded antisense protein and its association with autophagy.

Authors:  Cynthia Torresilla; Émilie Larocque; Sébastien Landry; Marilène Halin; Yan Coulombe; Jean-Yves Masson; Jean-Michel Mesnard; Benoit Barbeau
Journal:  J Virol       Date:  2013-02-20       Impact factor: 5.103

9.  Two hot spot mutant p53 mouse models display differential gain of function in tumorigenesis.

Authors:  W Hanel; N Marchenko; S Xu; S Xiaofeng Yu; W Weng; U Moll
Journal:  Cell Death Differ       Date:  2013-03-29       Impact factor: 15.828

Review 10.  Sorting out the trash: the spatial nature of eukaryotic protein quality control.

Authors:  Emily Mitchell Sontag; Willianne I M Vonk; Judith Frydman
Journal:  Curr Opin Cell Biol       Date:  2014-01-23       Impact factor: 8.382

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.